HKG:2607 Revenue

Shanghai Pharmaceuticals Holding had revenue of 70.76B CNY in the quarter ending March 31, 2025, with 0.87% growth. This brings the company's revenue in the last twelve months to 275.86B, up 4.41% year-over-year. In the year 2024, Shanghai Pharmaceuticals Holding had annual revenue of 275.25B with 5.75% growth.

Revenue (ttm)

275.86B CNY

Revenue Growth

+4.41%

P/S Ratio

0.24

Revenue / Employee

5.58M CNY

Employees

49,402

Market Cap

69.70B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	275.25B	14.96B	5.75%
Dec 31, 2023	260.30B	28.31B	12.21%
Dec 31, 2022	231.98B	16.16B	7.49%
Dec 31, 2021	215.82B	23.92B	12.46%
Dec 31, 2020	191.91B	5.34B	2.86%
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2018	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2017	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2016	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2015	Upgrade Pro	Upgrade Pro	Upgrade Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
BeOne Medicines	32.49B
Hansoh Pharmaceutical Group Company	13.05B
JD Health International	61.89B
Innovent Biologics	10.03B
Akeso	2.26B
WuXi Biologics	19.87B
Sino Biopharmaceutical	30.72B
CSPC Pharmaceutical Group	28.99B

Revenue Rankings

Shanghai Pharmaceuticals Holding News

7 months ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
7 months ago - HUTCHMED to divest 45% stake in JV with Shanghai Pharma - Seeking Alpha

More News